SLC5A2 and diabetes mellitus: In a recent study Packer and colleagues demonstrated that receiving empagliflozin (SGLT2 inhibitor) in patients with heart failure was associated with BP control, renal protection, and lower risk of hospitalization for heart failure or cardiovascular death, both in patients with diabetes mellitus and patients without diabetes mellitus.38